Science Blog

The adoption of wearables into clinical trials is fostering innovative ideas about novel digital biomarker development. The following articles discuss strategies for developing respiratory endpoints using real-world data and a patient-centered approach. Learn more and advance ideas for your next research project!

There’s an undeniable push to drive innovation for a new age of precision medicine. At the 2021 Digital Biomarkers & Digital Measurements Summit, Kate Lyden, VivoSense Chief Science Officer, joined a panel of experts to discuss the future of digital biomarkers and advancing medicine toward a patient-oriented, decentralized, tech-enabled approach. Here is a quick snap-shot of her key takeaways.

In this video, Dudley Tabakin, VivoSense CEO, shares an example of how rare disease researchers can use wearable sensors to develop digital clinical measures to improve patient outcomes. He discusses our approach to developing outcome measures from ECG Derived Respiration (EDR) to discover novel respiratory endpoints for Rett Syndrome, working with Rett Syndrome Research Trust.

Millions of people across the globe struggle with neurodegenerative diseases every day. Neurodegenerative diseases are characterized by a breakdown of the central and peripheral nervous systems and cause progressive deterioration of a normally functioning human body. However, a significant challenge in studying neurodegenerative diseases is that direct measurements of neurological systems are invasive and expensive.

Wearable sensors can be used to understand disease progression and manifestation by measuring physical symptoms and physiological outcomes.

Respiratory abnormalities characterize a variety of disorders. In addition to physical disorders, ventilation is profoundly affected by mental and psychophysiological states, including stress, anxiety, and panic disorder. Let’s take a look at respiratory-related health issues and the promising wearable technology available to assess respiratory outcome measures in real-world settings.

When deploying wearable sensors in clinical trials, it is essential to understand how these are positioned on the body. The objective is to maximize the quality of the signal while minimizing burden and maintaining patient comfort. Sensor wear position impacts the accuracy and precision of digital clinical outcome measures.

Digital innovation in clinical trial research has been accelerated because of the COVID-19 pandemic. Wherever possible, in-clinical assessments are being replaced with measures taken outside the study site. Decentralized trials present a new challenge to accurately capture data in real-world settings, such as the home or workplace. Here we illustrate how an outcome measure from a wearable sensor can be used as an alternative to the 6-Minute Walk Test (6MWT).

Digital health technologies have the potential to transform clinical drug development. They can collect continuous, high-resolution data in patients’ real-world environments for extended periods of time, providing researchers with an unprecedented level of insight into patients’ physiological and behavioral states. These types of data may more accurately describe a patient’s experience and enable previously unattainable scientific undertakings.